InsidersTradesSigma
Total declarations
Companies
▲ Purchases (23 ops.)
▼ Sales (6 ops.)
Insider track record
CFODisclosed buys
23
Disclosed sells
6
T+90 hit rate
50%
T+90 mean return
+16.3%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by O'Toole David D, Chief Financial Officer. Director active across 2 companies, notably Opiant Pharmaceuticals, INC.. Aggregated, 37 filings have been published. Split: 23 buys · 6 sells. Total volume traded: €330k. Activity tracked since 16 August 2021. The latest transaction was disclosed on 29 May 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations37 total
2,000 sharesCommon StockSEC:0001193125-26-269544:0
5,000 shares@ US$3.05150.012% mcap5.1% of flowCommon StockSEC:0001193125-26-251588:0
2,000 shares@ US$4.240.0069% mcap2.9% of flowCommon StockSEC:0001193125-26-230874:0
Ideal exit: 13 Feb 2027 (T+270)
2,000 shares@ US$4.523.0% of flowCommon StockSEC:0000950170-25-111467:0
Ideal exit: 23 May 2026 (T+270)
2,000 shares@ US$4.813.2% of flowCommon StockSEC:0000950170-25-107387:0
Ideal exit: 9 May 2026 (T+270)
1,000 shares@ US$9.903.7% of flowCommon StockSEC:0000950170-25-024204:0
Ideal exit: 17 Nov 2025 (T+270)
1,000 shares@ US$10.253.8% of flowCommon StockSEC:0000950170-25-023233:0
Ideal exit: 16 Nov 2025 (T+270)
785 shares@ US$7.832.3% of flowCommon StockSEC:0000950170-24-133748:0
500 shares@ US$9.201.7% of flowCommon StockSEC:0000950170-24-068006:0
Ideal exit: 24 Feb 2025 (T+270)
1,000 shares@ US$17.386.3% of flowCommon StockSEC:0000950170-24-022050:0
Ideal exit: 24 Nov 2024 (T+270)
950 shares@ US$12.454.3% of flowCommon StockSEC:0000950170-23-069750:0
Ideal exit: 7 Sept 2024 (T+270)
1,034 shares@ US$9.0613.3% of flowCommon StockSEC:0000950170-23-067875:0
1,000 shares@ US$10.303.7% of flowCommon StockSEC:0000950170-23-065502:0
Ideal exit: 17 Aug 2024 (T+270)
1,000 shares@ US$10.263.7% of flowCommon StockSEC:0000950170-23-065502:1
Ideal exit: 17 Aug 2024 (T+270)
1,000 shares@ US$12.154.4% of flowCommon StockSEC:0000950170-23-064444:0
Ideal exit: 12 Aug 2024 (T+270)
1,000 shares@ US$12.884.7% of flowCommon StockSEC:0000950170-23-064208:0
Ideal exit: 10 Aug 2024 (T+270)
1,000 shares@ US$17.056.1% of flowCommon StockSEC:0000950170-23-043056:0
Ideal exit: 12 May 2024 (T+270)
1,000 shares@ US$17.926.4% of flowCommon StockSEC:0000950170-23-042840:0
Ideal exit: 11 May 2024 (T+270)
1,000 shares@ US$17.896.4% of flowCommon StockSEC:0000950170-23-042840:1
Ideal exit: 11 May 2024 (T+270)
1,000 shares@ US$17.966.4% of flowCommon StockSEC:0000950170-23-042840:2
Ideal exit: 11 May 2024 (T+270)
1,000 shares@ US$17.946.4% of flowCommon StockSEC:0000950170-23-042840:3
Ideal exit: 11 May 2024 (T+270)
1,000 shares@ US$17.936.4% of flowCommon StockSEC:0000950170-23-042840:4
Ideal exit: 11 May 2024 (T+270)
1,000 shares@ US$16.155.8% of flowCommon StockSEC:0001209191-23-038909:0
Ideal exit: 16 Mar 2024 (T+270)
22,512 shares@ US$20.0080.6% of flowCommon StockSEC:0001385508-23-000053:0
541 shares@ US$20.261.9% of flowCommon StockSEC:0001385508-23-000030:0
25 of 37 declarations
About O'Toole David D
David D. O'Toole is the Chief Financial Officer of Opiant Pharmaceuticals, Inc., a company specializing in developing treatments for substance use disorders. In this role, he oversees the financial management of the company, including financial planning and analysis. With expertise in finance, he contributes to the company's financial strategy.
